Journal of Current Glaucoma Practice

Register      Login

VOLUME 11 , ISSUE 1 ( January-April, 2017 ) > List of Articles

Original Article

Incidence of Intraocular Pressure Elevation following Intravitreal Ranibizumab (Lucentis) for Age-related Macular Degeneration

Gustavo MSM Reis, John Grigg, Brian Chua, Anne Lee, Ridia Lim, Ralph Higgins, Alessandra Martins, Ivan Goldberg, Colin I Clement

Keywords : Age-related macular degeneration, Intraocular pressure, Ranibizumab

Citation Information : Reis GM, Grigg J, Chua B, Lee A, Lim R, Higgins R, Martins A, Goldberg I, Clement CI. Incidence of Intraocular Pressure Elevation following Intravitreal Ranibizumab (Lucentis) for Age-related Macular Degeneration. J Curr Glaucoma Pract 2017; 11 (1):3-7.

DOI: 10.5005/jp-journals-10008-1213

License: CC BY-NC 4.0

Published Online: 00-04-2017

Copyright Statement:  Copyright © 2017; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Aim: The aim of this article is to evaluate the rate of patients developing sustained elevated intraocular pressure (IOP) after ranibizumab (Lucentis) intravitreal (IVT) injections. Design: This is a retrospective study. Participants: Charts of 192 consecutive patients receiving Lucentis for age-related macular degeneration (AMD) were retrospectively reviewed. Materials and methods: We enrolled patients with at least two IOP measurements between injections. Elevated IOP was defined as >21 mm Hg with an increase of at least 20% from baseline. Noninjected contralateral eyes of the same patient cohort were used as control. Main outcome measures: Primary outcome was defined as elevated IOP. Secondary outcomes were presence and type of glaucoma, number of injections, and time to IOP elevation. Results: Elevated IOP occurred at a significantly higher rate in eyes receiving IVT ranibizumab (7.47%; n = 9) compared with control (0.93%; n = 1). Patients with preexisting glaucoma or ocular hypertension (OHT) were more likely to develop elevated IOP after IVT ranibizumab injection. Conclusion: Intravitreal ranibizumab injections are associated with sustained IOP elevation in some eyes. How to cite this article: Reis GMSM, Grigg J, Chua B, Lee A, Lim R, Higgins R, Martins A, Goldberg I, Clement CI. The Incidence of Intraocular Pressure Elevation following Intravitreal Ranibizumab (Lucentis) for Age-related Macular Degeneration. J Curr Glaucoma Pract 2017;11(1):3-7.


PDF Share
  1. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP. Global data on visual impairment in the year 2002. Bull World Health Organ 2004 Nov;82(11):844-849.
  2. Bakri SJ, McCannel CA, Edwards AO, Moshfeghi DM. Persistent ocular hypertension following IVT ranibizumab. Graefes Arch Clin Exp Ophthalmol 2008 Jul;246(7):955-958.
  3. Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, Giraldez J. Ranibizumab for neovascular age-related macular degeneration. Am J Health Syst Pharm 2008 Oct 1;65(19):1805-1814.
  4. Sharei V, Höhn F, Köhler T, Hattenbach LO, Mirshahi A. Course of intraocular pressure after intravitreal injections of 0.05 mL ranibizumab (Lucentis). Eur J Ophthalmol 2010 Jan-Feb;20(1):174-179.
  5. Loukianou E, Brouzas D, Apostolopoulos M. Sustained ocular hypertension following intravitreal injections of 0.5 mg/0.05 ml ranibizumab. Int Ophthalmol 2011 Jun;31(3):211-213.
  6. Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 2011 Aug;95(8):1111-1114.
  7. Adelman RA, Zheng Q, Mayer HR. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther 2010 Feb;26(1):105-110.
  8. Bressler SB, Almukhtar T, Bhorade A, Bressler NM, Gassman AR, Huang SS, Jampol LM, Kim JE, Melia M, Diabetic Retinopathy Clinical Research Network Investigators. Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment. JAMA Ophthalmol 2015 May;133(5):589-597.
  9. Freund KB, Hoang QV, Saroj N, Thompson D. Intraocular pressure in patients with neovascular age-related macular degeneration receiving intravitreal aflibercept or ranibizumab. Ophthalmology 2015 Sep;122(9):1802-1810.
  10. Agard E, Elchehab H, Ract-Madoux G, Russo A, Lagenaite C, Dot C. Repeated intravitreal anti-vascular endothelial growth factor injections can induce iatrogenic ocular hypertension, especially in patients with open-angle glaucoma. Can J Ophthalmol 2015 Apr;50(2):127-131.
  11. Dedania VS, Bakri SJ. Sustained elevation of intraocular pressure after intravitreal anti-VEGF agents: what is the evidence? Retina 2015 May;35(5):841-858.
  12. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005 Feb;46(2):726-733.
  13. Bakri S, Synder M, Reid J, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007 Dec;114(12):2179-2182.
  14. Thulliez M, Angoulvant D, Le Lez ML, Jonville-Bera AP, Pisella PJ, Gueyffier F, Bejan-Angoulvant T. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis. JAMA Ophthalmol 2014 Nov;132(11):1317-1326.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.